Lobeglitazone vs Pioglitazone (JT-001)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: PPAR-gamma · full Type 2 Diabetes pipeline

Lobeglitazone · Duvie

Marketed by Chong Kun Dang Pharmaceutical and partners

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT02002611 · Phase 1 · completed

Every participant received both lobeglitazone and warfarin, so there is no separate group showing what would have happened without lobeglitazone, and nobody was blinded to treatment. The measures collected were drug-level readings for a drug-interaction check, not a symptom or disease-based result, so this trial offers only limited evidence about lobeglitazone's own effects.

Next expected readout: September 2029 · NCT07108985 (registry estimate)

Reported efficacy

Change from baseline in Glycosylated Hemoglobin (HbA1c) (Baseline, 24 weeks): HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately. (met)

Result source: NCT03739125

Pioglitazone (JT-001)

Developed by Jeil Pharmaceutical

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT05101135 · Phase 3 · status unknown

This randomized, double-blind, placebo-controlled trial enrolled 256 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. JT-001 significantly reduced HbA1c versus placebo (p<0.0001), and more patients on JT-001 reached HbA1c targets of below 7% and 6.5%.

ClinicalTrials.gov still shows the planned enrollment of 256; the published report gives 262 randomized (131 per arm).

Reported efficacy

Changes in HbA1c (24th Week): JT-001 (pioglitazone 15mg) add-on vs placebo, week 24 HbA1c change: -0.47% (95% CI -0.61 to -0.33), P<0.0001. HbA1c<7% achieved: 56.8% vs 28%; HbA1c<6.5%: 23.2% vs 9.6% (P<0.0001 for all). (met)

Result source: NCT05101135

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLobeglitazonePioglitazone (JT-001)
HbA1c, change—Not posted · NCT01106131—Not reported
Body weight, change (kg)—Not posted · NCT01106131—Not reported
HbA1c below 7%—Not posted · NCT01106131—Not reported
Fasting plasma glucose, change—Not posted · NCT01106131—Not reported
3-point MACE (% with event)—Not posted · NCT01106131—Not reported

HbA1c, change

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone (JT-001)
—Not reported

Body weight, change (kg)

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone (JT-001)
—Not reported

HbA1c below 7%

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone (JT-001)
—Not reported

Fasting plasma glucose, change

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone (JT-001)
—Not reported

3-point MACE (% with event)

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone (JT-001)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Lobeglitazone
Drug-drug interaction study in healthy subjects: for warfarin AUC, the geometric mean ratios for warfarin plus lobeglitazone compared to warfarin alone were 1.0076 for R-warfarin and 0.9880 for S-warfarin, and maximum observed plasma concentration values were 1.0167 and 1.0028, all contained in the interval 0.80 to 1.25. Lobeglitazone had no effect on the area under the effect-time curve of INR or factor VII activity (geometric mean ratios 1.0091 and 0.9355) and no meaningful effect on the pharmacokinetics or pharmacodynamics of warfarin; concomitant administration was well tolerated. NCT02002611 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result
HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately. NCT03739125 · Phase 3 · design grade: moderate · publication or press release
HbA1c change at week 24: -0.74% lobeglitazone vs -0.74% pioglitazone (difference 0.01%, 95% CI -0.16 to 0.18); noninferior. NCT01106131 · Phase 3 · design grade: moderate · publication or press release
Pioglitazone (JT-001)
JT-001 (pioglitazone 15mg) add-on vs placebo, week 24 HbA1c change: -0.47% (95% CI -0.61 to -0.33), P<0.0001. HbA1c<7% achieved: 56.8% vs 28%; HbA1c<6.5%: 23.2% vs 9.6% (P<0.0001 for all). NCT05101135 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lobeglitazone's landscape · Pioglitazone (JT-001)'s landscape